Sabra Healthcare REIT (SBRA) Financials

Sabra Healthcare REIT’s latest results show a business that is still generating solid operating cash flow, but with leverage, heavy depreciation, and recurring special charges keeping reported earnings under pressure. Over the last several years, the company has maintained positive quarterly net income in most periods, while cash from operations has stayed relatively strong. At the same time, debt remains elevated and quarter-to-quarter volatility in non-operating items makes the earnings profile less predictable for retail investors.

What stands out most in Q1 2026: Sabra produced $40.8 million of net income attributable to common shareholders and $98.4 million of operating cash flow. That’s a healthy cash-generating quarter, especially given $53.1 million of depreciation, which is a non-cash expense that reduces accounting earnings but not immediate cash flow. The company also ended the quarter with $116.5 million of cash and equivalents, up sharply from $200.6 million in Q3 2025, while total assets rose to $5.59 billion.

Longer-term trend: from 2023 through early 2026, operating cash flow has generally ranged between roughly $52 million and $109 million per quarter, showing a fairly durable cash engine. However, net income has been choppy, swinging from a loss in Q1 2023 to strong profit in later periods, then easing again in some quarters. This suggests the business is cash-flow oriented, but reported earnings are influenced by sizable special items and property-level expenses.

• Operating cash flow remains strong: Q1 2026 operating cash flow of $98.4 million was solid and well above dividends paid in the quarter.
• Liquidity improved materially: cash and equivalents rose to $116.5 million in Q1 2026 from $200.6 million in Q3 2025 after a dip in Q4 2025, giving the company more balance-sheet flexibility.
• Net income rebounded: Q1 2026 net income attributable to common shareholders was $40.9 million, up from $27.2 million in Q4 2025 and $22.5 million in Q3 2025.
• Revenue remained resilient: Q1 2026 total revenue was $193.3 million, higher than Q4 2025 and Q3 2025, showing continued top-line stability.
• Shares outstanding remain relatively controlled: diluted shares in Q1 2026 were 256.0 million versus 244.5 million in Q4 2025, but the increase is not yet dramatic enough to overwhelm earnings growth.
• Depreciation is consistently large: quarterly depreciation has been around the low-$40 million to low-$50 million range, which depresses reported earnings but is common in REIT-style asset-heavy businesses.
• Dividend coverage appears reasonable from cash flow: Q1 2026 operating cash flow exceeded the quarterly dividend paid, though dividend sustainability should still be monitored against debt and capital needs.
• Asset base is stable to slightly growing: total assets increased to $5.59 billion in Q1 2026 from $5.23 billion in Q1 2025 and $5.37 billion in Q1 2024.
• Debt remains a major obligation: Q1 2026 total debt was about $2.67 billion, including $355.0 million of short-term debt and $2.31 billion of long-term debt.
• Special charges remain high and unpredictable: Q1 2026 included $85.6 million of other special charges, and prior quarters also showed large special charges and impairment costs.

Balance-sheet leverage is the biggest thing investors should watch. At Q1 2026, total liabilities were $2.80 billion versus $2.79 billion of total equity and noncontrolling interests, indicating a fairly leveraged structure. That is not unusual for a REIT, but it leaves less room for error if interest rates stay elevated or if operating performance weakens.

Interest expense is still meaningful: Q1 2026 total interest expense was $28.4 million, only slightly lower than the prior year’s nearby quarters. While not alarming relative to cash flow, it does limit earnings power and makes debt management important.

Bottom line: SBRA looks like a company with decent cash-generation capability and improving near-term liquidity, but investors should not ignore the leverage and the recurring special charges. The stock’s long-term appeal likely depends on whether Sabra can keep operating cash flow steady while gradually reducing debt pressure and avoiding large one-time hits to earnings.